TB[e]Education kickoff in Kampala, Uganda, 2009
TB[e]Education
Tuberculosis infection is a growing problem worldwide, directly related to HIV infection rates. Thus, healthcare workers in HIV/AIDS need to be aware of tuberculosis (TB) coinfection complications, the Immune Reconstitution Inflammatory Syndrome, and the rise of multi-drug resistant and extensive drug resistant strains of TB.
TB[e]Education was initiated during the international AIDS conference in Toronto, Canada, in August 2006. A special scientific advisory board headed by Mario Raviglione (Director of STOP TB, WHO) was formed, and world renowned experts have contributed to the content.
Scientific Advisory Board
Mario Raviglione, WHO, Geneva,
Switzerland
Martien Borgdorff, GGD Amsterdam, The Netherlands
Jerrold Ellner, Boston University, USA
Anton Pozniak, Chelsea and Westminster
Hospital, London
Jerrold Sadoff, Crucell Holland B.V.,
Leiden, The Netherlands
“We cannot win the battle against AIDS if we do not also fight TB." (Nelson Mandela)
English
Portuguese
Modules & Authors
Global Epidemiology and the Control of TB
Philippe Glaziou &
Christopher Dye, World Health Organization, Geneva, Switzerland
Clinical Management of TB in HIV Positive Patients
Anthony D. Harries,
International Union against Tuberculosis and Lung Disease, Paris, France, and London
School of Hygiene and Tropical Medicine, London, UK
Rony Zachariah, Médecins sans
Frontières, Operational Research Unit, Medical Department, Brussels-Luxembourg
Tuberculosis and Drug-drug Interactions
Rob Aarnoutse,
Department of Clinical Pharmacy, Radboud University Nijmegen Medical Center,
The Netherlands
MDR-TB/ XDR-TB
Agnes Gebhard, KNCV
TB Foundation, The Hague, The Netherlands
HIV-TB Co-infection and Treatment
Anton L. Pozniak, HIV
and Tuberculosis Services, St. Stephen's Centre, Chelsea and Westminster
Hospital, London, United Kingdom
Childhood Tuberculosis
Jeffrey R. Starke, Department
of Pediatrics, Baylor College of Medicine, Houston, USA
New Diagnostic Tools
Antonino Catanzaro, Pulmonary Department, School of Medicine,
University of California, San Diego, USA
New Drugs
Mel Spigelman, The
Global Alliance for TB Drug Development, New York, USA
A New Frontier in TB Vaccines
Jerry Sadoff, Crucell Holland
B.V., Leiden, The Netherlands
